BACKGROUND: Clinical abnormalities associated with drug therapy may lead to injury if untreated. Detection of preceding drug-related hazardous conditions (DRHCs) may provide the opportunity to prevent injury. This study evaluated the frequency of abnormal laboratory values attributed to the effect of drugs. METHODS: A total of 590 patients consecutively admitted to a surgical intensive care unit during a 3-month period were prospectively studied. Serum electrolyte, platelet, creatinine, glucose, magnesium, and liver enzyme concentrations were classified as either normal or abnormal using standard criteria. DRHCs were abnormal laboratory results determined to be caused by drugs. RESULTS: DRHCs were detected in 16.4% of patients, reflecting a rate of 47 events per 1,000 patient days. 66%, 22%, and 12% of DRHCs were categorized as either definite, probable, or possible, respectively. In 97% of suspected DRHCs, clinicians responded by ordering additional laboratory tests or changing drug regimens. CONCLUSIONS: Monitoring laboratory values and assessing the association to medications may reduce the risk of injury consequent to adverse drug events.
BACKGROUND: Clinical abnormalities associated with drug therapy may lead to injury if untreated. Detection of preceding drug-related hazardous conditions (DRHCs) may provide the opportunity to prevent injury. This study evaluated the frequency of abnormal laboratory values attributed to the effect of drugs. METHODS: A total of 590 patients consecutively admitted to a surgical intensive care unit during a 3-month period were prospectively studied. Serum electrolyte, platelet, creatinine, glucose, magnesium, and liver enzyme concentrations were classified as either normal or abnormal using standard criteria. DRHCs were abnormal laboratory results determined to be caused by drugs. RESULTS: DRHCs were detected in 16.4% of patients, reflecting a rate of 47 events per 1,000 patient days. 66%, 22%, and 12% of DRHCs were categorized as either definite, probable, or possible, respectively. In 97% of suspected DRHCs, clinicians responded by ordering additional laboratory tests or changing drug regimens. CONCLUSIONS: Monitoring laboratory values and assessing the association to medications may reduce the risk of injury consequent to adverse drug events.
Authors: Sara Ibáñez-Garcia; Carmen Rodriguez-Gonzalez; Vicente Escudero-Vilaplana; Maria Luisa Martin-Barbero; Belén Marzal-Alfaro; Jose Luis De la Rosa-Triviño; Irene Iglesias-Peinado; Ana Herranz-Alonso; Maria Sanjurjo Saez Journal: Appl Clin Inform Date: 2019-07-17 Impact factor: 2.342
Authors: Laura E Miller; Chris DeRienzo; P Brian Smith; Carl Bose; Reese H Clark; C Michael Cotten; Daniel K Benjamin; Chi D Hornik; Rachel G Greenberg Journal: J Perinatol Date: 2020-10-08 Impact factor: 2.521
Authors: Sandra L Kane-Gill; Shyam Visweswaran; Melissa I Saul; An-Kwok Ian Wong; Louis E Penrod; Steven M Handler Journal: Int J Med Inform Date: 2011-05-31 Impact factor: 4.046
Authors: Mitchell S Buckley; Jeffrey R Rasmussen; Dale S Bikin; Emily C Richards; Andrew J Berry; Mark A Culver; Ryan M Rivosecchi; Sandra L Kane-Gill Journal: Ther Adv Drug Saf Date: 2018-03-01
Authors: Jaclyn M LeBlanc; Kayla Cameron-Coffill; Jodi L Symes; Sandra Kane-Gill; Kevin Duplisea; John Mowatt Journal: Can J Hosp Pharm Date: 2017-02-28